BioPharma

MedCity Pivot Podcast: A conversation with Aetion’s CEO about the growing emphasis of Real World Evidence

In this episode of the MedCity Pivot Podcast, Carolyn Magill, CEO of Aetion, explains the growing importance of Real World Evidence in the world of pharma and how the company is collaborating with the FDA to gain a better understanding of Covid-19.

Health tech companies – especially digital therapeutics ones – have had a tough time working with pharma companies. Among tech vendors, Aetion is an exception in that category. It has developed a Real-World Evidence (RWE) platform being used by Sanofi and other pharma companies.

As Covid-19 hit, the New York company entered into a research collaboration with the Food and Drug Administration to facilitate the understanding of what treatments are more effective in countering the SARS-CoV-2 virus that has claimed the lives of so many around the world.

presented by

In this episode of the MedCity pivot podcast, Aetion’s CEO, Carolyn Magill, talks about the importance of RWE and how it is being used in new drug applications and in negotiating value-based contracts. Here’s the full episode: